[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598756":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":19,"locations":25,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Addario Lung Cancer Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"SCLC",null,"Diagnosis of SCLC within 1 year of enrollment",[13,17],{"name":14,"affiliation":15,"role":16},"Jacob Sands, MD","Dana-Farber Cancer Institute","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":15,"role":16},"Gilbert Youssef, MD",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Allison M Harper, PharmD","CONTACT","704-996-6579","aharper@alcmi.org",[26],{"facility":15,"status":10,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Boston","Massachusetts","02215","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-71.05977,42.35843,{"lat":36,"lon":35},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100598756","a-study-to-evaluate-the-incidence-of-clinically-suspicious-lambert-eaton-myasthenic-syndrome-lems-in-subjects-diagnosed-with-small-cell-lung-cancer-sclc-100598756",false,"NCT07075627","A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)","An Observational Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n1. Adult men or women meeting Age of Majority (AOM) at the time of consent\n2. Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF)\n3. Any diagnosis of SCLC\n4. Willing to provide clinical and medical information related to his\u002Fher cancer diagnoses to the study team as required\n5. Willing to comply with the requirements of the study\n\nExclusion Criteria:\n\n1. Has been diagnosed with non-tumor Lamber-Eaton Myasthenic syndrome (LEMS) \\> 1 year prior to the SCLC diagnosis.\n2. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements","ALL","18 Years",{"count":50,"type":51},400,"ESTIMATED","OBSERVATIONAL","This is a multi-center observational study in subjects with a diagnosis of small cell lung cancer. Screening and\u002For medical record review for symptoms associated with Lambert Eaton Myasthenic Syndrome (LEMS) will be conducted.",[55,56],"Small Cell Lung Cancer ( SCLC )","Lambert Eaton Myasthenic Syndrome (LEMS)",[9,58,59,60],"LEMS","small cell lung cancer","lambert eaton myasthenic syndrome","NOT_YET_RECRUITING","2025-07-30",{"date":64,"type":65},"2025-08-01","ACTUAL",{"date":67,"type":51},"2025-09",{"date":69,"type":51},"2026-12",{"name":5,"class":6},1]